For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The North America hyperphosphatemia drug market is expected to grow at a CAGR of 15.19% over the forecast period. The region is expected to hold the largest share in the market with an anticipated increase in the revenue from $xx million in 2018 to $xx million by 2027. Diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. Increasing prevalence of these chronic diseases along with unattended medical needs are driving the hyperphosphatemia drug market in this region.
The changing dietary patterns along with the increasing cases of osteoporosis diseases in countries like the United States and Canada are providing the hyperphosphatemia drug market with plenty of growth opportunities. The market is mainly categorized by the different types of drug binders such as iron-based phosphate binders, magnesium-based phosphate binders, aluminium-based phosphate binders, calcium-based phosphate binders and others. The aluminium-based phosphate binders generated revenue of $203 million in 2016 and are widely used with magnesium-based phosphate binders for treating patients on dialysis. However, it is the calcium-based phosphate binders that held the largest market share of xx% in 2018 and are expected to continue their dominance throughout the forecasted period. Despite such phenomenal growth, the market is facing some tough challenges due to the various limitations imposed by the Food and Drug Administration (FDA) and the rising side effects observed due to the use of some of the hyperphosphatemia drugs.
Some of the eminent companies in the hyperphosphatemia drug market include Royal Dsm, Amag, Sun Pharma, and Keryx. Other top players in the market are Zeria Pharmaceutical, Johnson and Johnson, Bruno Pharmaceutical Spa, Cipla, Ultragenyx, Fresenius Medical Care, Roche Diagnostics Corporation, R.H. Moore Drug Co., Sanofi, Fermenta Biotech Ltd, Vifor Pharma, Shire and Pfizer Inc.